PF-03550096 is a drug that acts as a potent agonist for the CB<sub>2</sub> cannabinoid receptor, with good selectivity over CB<sub>1</sub> having K<sub>i</sub> values of 7nM at CB<sub>2</sub> and 1500nM at CB<sub>1</sub>. It was originally developed by Pfizer in 2008 as a medication for irritable bowel syndrome, but has only progressed to animal studies.